Taken together, these observations raise the possibility that reduced levels of striatal BDNF may significantly contribute to the HD pathogenesis and identify BDNF-TrkB signaling pathway as a potential therapeutic target for HD treatment. The gene discussed is NTRK2; the disease is Huntington disease.